Generic Drug Puzzle: Why Did ANDA Submissions Spike Again?
Jump in March may have been "happenstance," but also could be concerning as US ANDA submissions reach near record pace.
You may also be interested in...
US agency could reconsider requirement that instructions for use be same for branded and generic products, FDA Commissioner-nominee Scott Gottlieb suggests, while also leaving door open to statutory changes in Hatch-Waxman Act.
Industry representatives support adding a provision to the user fee agreements that would withdraw some taxpayer funding if the agency does not meet its deliverables.
Suggested cuts to appropriations bill funding government for remainder of fiscal year 2017 also includes 'administrative savings.'